MEDI 312-Discovery of YM155, a novel survivin suppressant for the treatment of cancer

被引：0

作者：

Kinoyama, Isao ^{[1
]}

Matsuhisa, Akira ^{[1
]}

Nakahara, Takahito ^{[1
]}

Takeuchi, Masahiro ^{[1
]}

Shirasuna, Kenna ^{[1
]}

Minematsu, Tsuyoshi ^{[1
]}

Asai, Norio ^{[1
]}

Matsumoto, Shunichiro ^{[1
]}

Kawaguchi, Kenichi ^{[1
]}

Kazami, Junichi ^{[1
]}

Toyoshima, Akira ^{[1
]}

Kita, Aya ^{[1
]}

Tominaga, Fumiko ^{[1
]}

Okada, Minoru ^{[1
]}

Ohta, Mitsuaki ^{[1
]}

机构：

[1] Astellas Pharma Inc, Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 234卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

312-MEDI

引用

页数：1

共 50 条

[41] YM155, a novel small molecule survivin suppressant, exhibits curative antitumor activities in experimental human malignant lymphoma models in vivo
Kita, A.
Nakahara, T.
Yamanaka, K.
Koutoku, H.
Takeuchi, M.
Kinoyama, I.
Matsuhisa, A.
Sasamata, M.
EJC SUPPLEMENTS, 2006, 4 (12): : 116 - 116
[42] Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma
Wang, Yu-Fan
Zhang, Wei
He, Ke-Fei
Liu, Bing
Zhang, Lu
Zhang, Wen-Feng
Kulkarni, Ashok B.
Zhao, Yi-Fang
Sun, Zhi-Jun
APOPTOSIS, 2014, 19 (04) : 748 - 758
[43] A phase II, monotherapy study of YM155, a novel survivin suppressant, in previously treated advanced stage non-small cell lung cancer (NSCLC)
Giaccone, Giuseppe
Zatloukal, Petr
Roubec, Jaromir
Musil, Jaromir
Kuta, Milan
van Klaveren, R. J.
Chaudhary, Subhash
Gunther, Adrie
Shamsili, Setareh
Kazei, Dmitri
Verbeeck, Frank
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3597S - 3597S
[44] Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model
Murakami, Yoshihiro
Matsuya, Takahiro
Kita, Aya
Yamanaka, Kentaro
Noda, Akihiro
Mitsuoka, Keisuke
Nakahara, Takahito
Miyoshi, Sosuke
Nishimura, Shintaro
NUCLEAR MEDICINE AND BIOLOGY, 2013, 40 (02) : 221 - 226
[45] Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan
Nakagawa, K.
Satoh, T.
Okamoto, I.
Miyazaki, M.
Morinaga, R.
Tsuya, A.
Hasegawa, Y.
Terashima, M.
Ueda, S.
Fukuoka, M.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[46] YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
Nakahara, Takahito
Takeuchi, Masahiro
Kinoyama, Isao
Minematsu, Tsuyoshi
Shirasuna, Kenna
Matsuhisa, Akira
Kita, Aya
Tominaga, Fumiko
Yamanaka, Kentaro
Kudoh, Masafumi
Sasamata, Masao
CANCER RESEARCH, 2007, 67 (17) : 8014 - 8021
[47] The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model
de Haart, Sanne J.
Minnema, Monique C.
Huang, Julie H.
Aarts-Riemens, Tineke
Lokhorst, Henk
Martens, Anton
Mitsiades, Constantine S.
Mutis, Tuna
BLOOD, 2013, 122 (21)
[48] A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
Cheson, Bruce D.
Bartlett, Nancy L.
Vose, Julie M.
Lopez-Hernandez, Andres
Seiz, Amanda L.
Keating, Anne T.
Shamsili, Setareh
CANCER, 2012, 118 (12) : 3128 - 3134
[49] A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors.
Tolcher, A. W.
Antonia, S.
Lewis, L. D.
Mita, A.
Mahany, J., Jr.
Reddy, N. J.
Till, E.
Buell, D.
Keating, T.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 124S - 124S
[50] Disruption of survivin protein expression by treatment with YM155 accelerates the resolution of neutrophilic inflammation
Fernandes, Debora de Oliveira
Machado, Jessica Rayssa
Beltrami, Vinicius Amorim
Dos Santos, Anna Clara Paiva Menezes
Queiroz-Junior, Celso Martins
Vago, Juliana Priscila
Soriani, Frederico Marianetti
Amaral, Flavio Almeida
Teixeira, Mauro Martins
Felix, Franciel Batista
Pinho, Vanessa
BRITISH JOURNAL OF PHARMACOLOGY, 2025, 182 (05) : 1206 - 1222

← 1 2 3 4 5 →